-
Product Insights
Smoking Cessation – Drugs In Development, 2023
Global Markets Direct’s, ‘Smoking Cessation - Drugs In Development, 2023’, provides an overview of the Smoking Cessation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuromuscular Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromuscular Disorders - Drugs In Development, 2023’, provides an overview of the Neuromuscular Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2023’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Tauopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Tauopathies - Drugs In Development, 2023’, provides an overview of the Tauopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Drugs In Development, 2023’, provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Insomnia – Drugs In Development, 2023
Global Markets Direct’s, ‘Insomnia - Drugs In Development, 2023’, provides an overview of the Insomnia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...